Boston Scientific reported $5.065 billion in net sales for the third quarter of 2025, driven largely by demand for cardiovascular devices.
The company’s cardiovascular segment grew 22.4% year over year on a reported basis, with strong performance from both cardiology and peripheral interventions. U.S. sales rose 27% overall, according to an Oct. 22 news release.
GAAP net income attributable to common stockholders reached $755 million, or $0.51 per share, up from $469 million and $0.32 per share a year prior. Adjusted earnings were $0.75 per share.
The devicemaker also raised its full-year guidance, projecting adjusted earnings of $3.02 to $3.04 per share and organic sales growth of 15.5%.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
